National Organization to Examine Role of Invokana® in Diabetic Ketoacidosis
The American Association of Clinical Endocrinologists will hold a conference in Dallas, TX this fall to examine the potential link of SLGT2 Inhibitors such as Invokana®, Farxiga®, and Jardiance® to diabetic ketoacidosis. The conference is said to include scientists, doctors, and diabetes experts that have studied available information in an effort to provide recommendations to doctors and patients.
Invokana® was the first SLGT2 inhibitor approved by the FDA. It is marketed as a cutting edge drug in the fight against Type 2 Diabetes. Invokana® is only approved to treat Type 2 Diabetes at this juncture. However, Invokana® was a highly criticized approval by the FDA, some going so far as to call Invokana® a “Questionable New Diabetes Drug.”
FDA Warns of Possible Invokana® Link to Diabetic Ketoacidosis
The FDA released a safety warning in May, 2015 warning of the risk of diabetic ketoacidosis while on Invokana®, Farxiga®, Jardiance®, and the other SLGT2 Inhibitors. While not a recall of these drugs, the warning was significant in that it noted 20 instances of diabetic ketoacidosis, ketoacidosis, or ketosis over a one year period. All of these disorders are potentially deadly.
Atlanta, GA Invokana® Attorneys Taking Lead in Warning Consumers
The Metro Atlanta, Georgia Invokana® Attorneys of The Parian Law Firm, LLC have spoken with people all over America about problems they attribute to Invokana®, Farxiga®, and Jardiance®. If you or a loved one has suffered any kidney problems or possible ketoacidosis while on the drugs, call our Atlanta Invokana® Attorneys at (770) 727-5550 or chat online with us now. You deserve to be informed.
